Pharma Mar SA operates within the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Pharma Mar SA with three other
miscellaneous service companies in Europe:
sales of 2.01 billion Norwegian Kroner [US$241.46 million]
Bachem Holding AG
(402.00 million Swiss Francs [US$437.43 million]
of which 90%
was Active Pharmaceutical Ingredients), and
based in GERMANY
(327.70 million Euros [US$381.49 million]
of which 85%
was Proprietary Development).
During the second
quarter of 2021, sales at Pharma Mar SA totalled
47.43 million Euro.
This is a drop of 31.9%
from the 69.66 million Euro in sales at the company during the second quarter in 2020.
During the first two
quarters of 2021, sales totalled 98.69 million Euro, which is
than through the first two quarters of 2020.
Sales increased substantially in 2020:
During the year ended December of 2020, sales at
Pharma Mar SA were 269.96 million Euro (US$314.27 million).
increase of 214.6%
versus 2019, when the company's sales were 85.82 million Euro.